Akarna Therapeutics closes $15 mln Series B
Drug developer Akarna Therapeutics Ltd raised $15 million in a Series B preferred stock financing round. New investor Forbion Capital Partners joined existing backers New Science Ventures and Third Point Ventures to complete the round.
16 February 2016•4 mins read
